Toward Personalized Medicine in Bardet–Biedl Syndrome

References

• Wrighton KH . Cell signalling: ciliary phosphoinositides regulate hedgehog signalling . Nat. Rev. Mol. Cell Biol.16 ( 10 ), 577 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wallingford JB , MitchellB . Strange as it may seem: the many links between Wnt signaling, planar cell polarity, and cilia . Genes Dev.25 ( 3 ), 201 – 213 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gerhardt C , LeuT , LierJM , RutherU . The cilia-regulated proteasome and its role in the development of ciliopathies and cancer . Cilia5 , 14 ( 2016 ).
   PubMedGoogle Scholar
• Nachury MV , LoktevAV , ZhangQet al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis . Cell129 ( 6 ), 1201 – 1213 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Seo S , BayeLM , SchulzNPet al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly . Proc. Natl Acad. Sci. USA107 ( 4 ), 1488 – 1493 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tobin JL , BealesPL . The nonmotile ciliopathies . Genet. Med.11 ( 6 ), 386 – 402 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Forsythe E , BealesPL . Bardet–Biedl syndrome . In : GeneReviews^® . PagonRA , AdamMP , ArdingerHHet al. ( Eds ). University of Washington , WA, USA ( 1993 ).
   Google Scholar
• Hjortshoj TD , GronskovK , Brondum-NielsenK , RosenbergT . A novel founder BBS1 mutation explains a unique high prevalence of Bardet–Biedl syndrome in the Faroe Islands . Br. J. Ophthalmol.93 ( 3 ), 409 – 413 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Moore SJ , GreenJS , FanYet al. Clinical and genetic epidemiology of Bardet–Biedl syndrome in Newfoundland: a 22 year prospective, population-based, cohort study . Am. J. Med. Genet. A132A ( 4 ), 352 – 360 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Farag TI , TeebiAS . High incidence of Bardet–Biedl syndrome among the Bedouin . Clin. Genet.36 ( 6 ), 463 – 464 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Eichers ER , LewisRA , KatsanisN , LupskiJR . Triallelic inheritance: a bridge between Mendelian and multifactorial traits . Ann. Med.36 ( 4 ), 262 – 272 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Beales PL , BadanoJL , RossAJet al. Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet–Biedl syndrome . Am. J. Hum. Genet.72 ( 5 ), 1187 – 1199 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Katsanis N , AnsleySJ , BadanoJLet al. Triallelic inheritance in Bardet–Biedl syndrome, a Mendelian recessive disorder . Science (NY)293 ( 5538 ), 2256 – 2259 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Khan SA , MuhammadN , KhanMA , KamalA , RehmanZU , KhanS . Genetics of human Bardet–Biedl syndrome, an updates . Clin. Genet.90 ( 1 ), 3 – 15 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Schaefer E , StoetzelC , ScheideckerSet al. Identification of a novel mutation confirms the implication of IFT172 (BBS20) in Bardet–Biedl syndrome . J. Hum. Genet.61 ( 5 ), 447 – 450 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Heon E , KimG , QinSet al. Mutations in C8ORF37 cause Bardet–Biedl syndrome (BBS21) . Hum. Mol. Genet.25 ( 11 ), 2283 – 2294 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Forsythe E , SparksK , BestSet al. Risk factors for severe renal disease in Bardet–Biedl syndrome . J. Am. Soc. Nephrol.28 ( 3 ), 963 – 970 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Khanna H , DavisEE , Murga-ZamalloaCAet al. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies . Nat. Genet.41 ( 6 ), 739 – 745 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Davis EE , ZhangQ , LiuQet al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum . Nat. Genet.43 ( 3 ), 189 – 196 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schaefer E , ZaloszycA , LauerJet al. Mutations in SDCCAG8/NPHP10 cause Bardet–Biedl syndrome and are associated with penetrant renal disease and absent polydactyly . Mol. Syndromol.1 ( 6 ), 273 – 281 ( 2011 ).
   PubMedGoogle Scholar
• Daniels AB , SandbergMA , ChenJ , Weigel-DifrancoC , Fielding HejtmancicJ , BersonEL . Genotype–phenotype correlations in Bardet–Biedl syndrome . Arch. Ophthalmol.130 ( 7 ), 901 – 907 ( 2012 ).
   PubMedGoogle Scholar
• Castro-Sanchez S , Alvarez-SattaM , CortonM , GuillenE , AyusoC , ValverdeD . Exploring genotype–phenotype relationships in Bardet–Biedl syndrome families . J. Med. Genet.52 ( 8 ), 503 – 513 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hulleman JD , NguyenA , RamprasadVLet al. A novel H395R mutation in MKKS/BBS6 causes retinitis pigmentosa and polydactyly without other findings of Bardet–Biedl or McKusick–Kaufman syndrome . Mol. Vis.22 , 73 – 81 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Irfanullah Khan S , UllahIet al. Hypomorphic MKS1 mutation in a Pakistani family with mild Joubert syndrome and atypical features: expanding the phenotypic spectrum of MKS1-related ciliopathies . Am. J. Med. Genet. A170 ( 12 ), 3289 – 3293 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Zaki MS , SattarS , MassoudiRA , GleesonJG . Co-occurrence of distinct ciliopathy diseases in single families suggests genetic modifiers . Am. J. Med. Genet. A155A ( 12 ), 3042 – 3049 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Coppieters F , LefeverS , LeroyBP , De BaereE . CEP290, a gene with many faces: mutation overview and presentation of CEP290base . Hum. Mutation31 ( 10 ), 1097 – 1108 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• EU Horizon 2020 Work Programme 2016–2017: Health, Demographic Change and Well-Being . European Union Commission (EU) . Brussles, Belgium ( 2016 ).
   Google Scholar
• Robinson PN . Deep phenotyping for precision medicine . Hum. Mutat.33 ( 5 ), 777 – 780 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• The Human Phenotype Ontology website ( 2016 ). www.human-phenotype-ontology.org .
   Google Scholar
• Onoufriadis A , ShoemarkA , SchmidtsMet al. Targeted NGS gene panel identifies mutations in RSPH1 causing primary ciliary dyskinesia and a common mechanism for ciliary central pair agenesis due to radial spoke defects . Hum. Mol. Genet.23 ( 13 ), 3362 – 3374 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Knopp C , Rudnik-SchonebornS , EggermannTet al. Syndromic ciliopathies: from single gene to multi gene analysis by SNP arrays and next generation sequencing . Mol. Cell Probes29 ( 5 ), 299 – 307 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kammermeier J , DruryS , JamesCTet al. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease – evaluation and prospective analysis . J. Med. Genet.51 ( 11 ), 748 – 755 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Belkadi A , BolzeA , ItanYet al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants . Proc. Natl Acad. Sci. USA112 ( 17 ), 5473 – 5478 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Scacheri CA , ScacheriPC . Mutations in the noncoding genome . Curr. Opin. Pediatr.27 ( 6 ), 659 – 664 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Otto EA , HurdTW , AirikRet al. Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy . Nat. Genet.42 ( 10 ), 840 – 850 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Badano JL , LeitchCC , AnsleySJet al. Dissection of epistasis in oligogenic Bardet–Biedl syndrome . Nature439 ( 7074 ), 326 – 330 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Seo S , MullinsRF , DumitrescuAVet al. Subretinal gene therapy of mice with Bardet–Biedl syndrome type 1 . Invest. Ophthalmol. Visual Sci.54 ( 9 ), 6118 – 6132 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Scholl HP , MooreAT , KoenekoopRKet al. Safety and proof-of-concept study of oral QLT091001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein (RPE65) or lecithin:retinol acyltransferase (LRAT) . PLoS ONE10 ( 12 ), e0143846 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rotenstreich Y , BelkinM , SadetzkiSet al. Treatment with 9-cis beta-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial . JAMA Ophthalmol.131 ( 8 ), 985 – 992 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nakazawa M , SuzukiY , ItoT , MetokiT , KudoT , OhguroH . Long-term effects of nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study . BioMed. Res. Int. 2013 , 585729 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kumar A , MidhaN , GogiaV , GuptaS , SehraS , ChohanA . Efficacy of oral valproic acid in patients with retinitis pigmentosa . J. Ocular Pharmacol. Ther.30 ( 7 ), 580 – 586 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hoffman DR , Hughbanks-WheatonDK , PearsonNSet al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial . JAMA Ophthalmol.132 ( 7 ), 866 – 873 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Falsini B , IarossiG , ChiarettiAet al. NGF eye-drops topical administration in patients with retinitis pigmentosa, a pilot study . J. Trans. Med.14 , 8 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Berson EL , RosnerB , SandbergMAet al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A . Arch. Ophthalmol.128 ( 4 ), 403 – 411 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Akiyama M , IkedaY , YoshidaNet al. Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa . Acta Ophthalmologica92 ( 3 ), e229 – 234 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Roy B , LeszykJD , MangusDA , JacobsonA . Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3 . Proc. Natl Acad. Sci. USA112 ( 10 ), 3038 – 3043 .
   PubMed Web of Science ®Google Scholar
• Tarantal AF , LeeCC , MartinezML , AravindA , SamulskiRJ . Systemic and persistent muscle gene expression in rhesus monkeys with a liver de-targeted adeno-associated virus (AAV) vector . Hum. Gene Therapy28 ( 5 ), 385 – 391 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Latorre-Rey LJ , WintterleS , DuttingSet al. Targeting expression to megakaryocytes and platelets by lineage-specific lentiviral vectors . J. Thromb. Haemost.15 ( 2 ), 341 – 355 ( 2016 ).
   Web of Science ®Google Scholar
• Zhong H , EblimitA , MoayediYet al. AAV8(Y733F)-mediated gene therapy in a Spata7 knockout mouse model of Leber congenital amaurosis and retinitis pigmentosa . Gene Therapy22 ( 8 ), 619 – 627 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mookherjee S , HiriyannaS , KaneshiroKet al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy . Hum. Mol. Genet.24 ( 22 ), 6446 – 6458 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lipinski DM , BarnardAR , SinghMSet al. CNTF gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa . Mol. Ther. J. Am. Soc. Gene Ther.23 ( 8 ), 1308 – 1319 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Simons DL , BoyeSL , HauswirthWW , WuSM . Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet–Biedl syndrome mouse model . Proc. Natl Acad. Sci. USA108 ( 15 ), 6276 – 6281 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wert KJ , Sancho-PelluzJ , TsangSH . Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa . Hum. Mol. Genet.23 ( 2 ), 514 – 523 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Maclaren RE , GroppeM , BarnardARet al. Retinal gene therapy in patients with choroideremia: initial findings from a Phase I/II clinical trial . Lancet383 ( 9923 ), 1129 – 1137 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• American Associantion of Ophthalmologists . Gene therapy for X-linked retinitis pigmentosa advances ( 2016 ). https://www.aao.org/headline/gene-therapy-x-linked-retinitis-pigmentosa-advance .
   Google Scholar
• Cong L , RanFA , CoxDet al. Multiplex genome engineering using CRISPR/Cas systems . Science (NY)339 ( 6121 ), 819 – 823 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kleinstiver BP , PattanayakV , PrewMSet al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects . Nature529 ( 7587 ), 490 – 495 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Salsman J , DellaireG . Precision genome editing in the CRISPR era . Biochem. Cell Biol.95 ( 2 ), 187 – 201 ( 2016 ).
   PubMedGoogle Scholar
• Honda A , HiroseM , SankaiTet al. Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9 . Exp. Anim.64 ( 1 ), 31 – 37 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Nakamura K , FujiiW , TsuboiMet al. Generation of muscular dystrophy model rats with a CRISPR/Cas system . Sci. Rep.4 , 5635 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dever DP , BakRO , ReinischAet al. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells . Nature539 ( 7629 ), 384 – 389 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Reardon S . First CRISPR clinical trial gets green light from US panel . Nature doi:10.1038/nature.2016.20137 ( 2016 ).
   Google Scholar
• Qasim W , ZhanH , SamarasingheSet al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells . Sci. Trans. Med.9 ( 374 ), ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Tebas P , SteinD , TangWWet al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV . N. Engl. J. Med.370 ( 10 ), 901 – 910 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Suzuki K , TsunekawaY , Hernandez-BenitezRet al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration . Nature540 ( 7631 ), 144 – 149 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Losson R , LacrouteF . Interference of nonsense mutations with eukaryotic messenger RNA stability . Proc. Natl Acad. Sci. USA76 ( 10 ), 5134 – 5137 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Lee HL , DoughertyJP . Pharmaceutical therapies to recode nonsense mutations in inherited diseases . Pharmacol. Ther.136 ( 2 ), 227 – 266 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Aslam AA , HigginsC , SinhaIP , SouthernKW . Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis . Cochrane1 , CD012040 ( 2017 ).
   PubMedGoogle Scholar
• Reinig AM , MirzaeiS , BerlauDJ . Advances in the treatment of Duchenne muscular dystrophy: new and emerging pharmacotherapies . Pharmacotherapy37 ( 4 ), 492 – 499 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Friesen WJ , TrottaCR , TomizawaYet al. The nucleoside analog clitocine is a potent and efficacious readthrough agent . RNA (NY)23 ( 4 ), 567 – 577 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Bacchi N , CasarosaS , DentiMA . Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter . Invest. Ophthalmol. Visual Sci.55 ( 5 ), 3285 – 3294 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kinali M , Arechavala-GomezaV , FengLet al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study . Lancet Neurol.8 ( 10 ), 918 – 928 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schmid F , GlausE , BarthelmesDet al. U1 snRNA-mediated gene therapeutic correction of splice defects caused by an exceptionally mild BBS mutation . Hum. Mutation32 ( 7 ), 815 – 824 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Collin RW , Den HollanderAI , Van Der Velde-VisserSD , BennicelliJ , BennettJ , CremersFP . Antisense oligonucleotide (AON)-based therapy for leber congenital amaurosis caused by a frequent mutation in CEP290 . Mol. Ther. Nucleic Acids1 , e14 ( 2012 ).
   PubMedGoogle Scholar
• Stagno F , StellaS , SpitaleriA , PennisiMS , Di RaimondoF , VigneriP . Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes . Exp. Rev. Anticancer Ther.16 ( 3 ), 273 – 278 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Clancy JP , JohnsonSG , YeeSWet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype . Clin. Pharmacol. Ther.95 ( 6 ), 592 – 597 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Quon BS , RoweSM . New and emerging targeted therapies for cystic fibrosis . BMJ352 , i859 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Khan NA , WillemarckN , TalebiAet al. Identification of drugs that restore primary cilium expression in cancer cells . Oncotarget7 ( 9 ), 9975 – 9992 ( 2016 ).
   PubMedGoogle Scholar
• Dalbay MT , ThorpeSD , ConnellyJT , ChappleJP , KnightMM . Adipogenic differentiation of hMSCs is mediated by recruitment of IGF-1r onto the primary cilium associated with cilia elongation . Stem Cells33 ( 6 ), 1952 – 1961 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Khan DA . Pharmacogenomics and adverse drug reactions: primetime and not ready for primetime tests . J. Allergy Clin. Immunol.138 ( 4 ), 943 – 955 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Alagoz O , DurhamD , KasirajanK . Cost–effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions . Pharmacogenomics J.16 ( 2 ), 129 – 136 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Bennett LL , TurcotteK . Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease . Drug Des. Devel. Ther.9 , 4639 – 4647 ( 2015 ).
   PubMed Web of Science ®Google Scholar